(NASDAQ: MRVI) Maravai Lifesciences Holdings's forecast annual revenue growth rate of -3.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 135.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.8%.
Maravai Lifesciences Holdings's revenue in 2025 is $241,856,000.On average, 5 Wall Street analysts forecast MRVI's revenue for 2025 to be $49,854,948,303, with the lowest MRVI revenue forecast at $47,986,766,086, and the highest MRVI revenue forecast at $52,205,200,985. On average, 5 Wall Street analysts forecast MRVI's revenue for 2026 to be $55,905,913,086, with the lowest MRVI revenue forecast at $53,631,294,280, and the highest MRVI revenue forecast at $59,633,619,096.
In 2027, MRVI is forecast to generate $69,167,816,753 in revenue, with the lowest revenue forecast at $64,370,286,112 and the highest revenue forecast at $73,965,347,394.